David Maughan, serving as the Chief Operating Officer for DaVita Kidney Care, a division of DaVita Inc. (NYSE:DVA), has liquidated a portion of his holdings in the company. The transactions involved a total of 20,529 shares of common stock, resulting in an approximate total value of $4,089,742.
Transaction Details
The divestment was executed across two consecutive trading days in May 2026. On May 11, 2026, Mr. Maughan sold 7,073 shares at a weighted average price of $199.149 per share. The individual sale prices for this specific lot ranged from a low of $199.000 to a high of $199.840.
The following day, May 12, 2026, the COO disposed of an additional 13,456 shares. This second tranche was sold at a weighted average price of $199.254 per share, with individual transaction prices also falling within the range of $199.000 to $199.840. Following these two rounds of selling, Mr. Maughan maintains a direct ownership stake of 94,105 shares of DaVita common stock.
Market Context and Financial Performance
These sales occurred while DaVita's stock was trading near its 52-week high of $202.69. The company has demonstrated substantial momentum this year, delivering a 76.5% return year-to-date. This performance follows a strong first-quarter 2026 earnings report where the company outperformed several key financial metrics. DaVita reported earnings per share (EPS) of $2.87, which exceeded the forecasted figure of $2.32. Furthermore, revenue for the quarter reached $3.42 billion, surpassing the anticipated $3.34 billion.
Analyst reactions to these results have been mixed regarding outlook and ratings. Deutsche Bank upgraded the stock from Hold to Buy, increasing its price target significantly from $126 to $220, citing a revenue per treatment of $417.59 that was higher than Wall Street expectations. Conversely, BofA Securities raised its price target from $130 to $145 but maintained an Underperform rating for the company.
Key Insights
- Executive Divestment at Valuation Peaks: The sale by a high-level executive occurs as the stock approaches its 52-week highs, which can impact investor sentiment in the healthcare services sector.
- Strong Operational Metrics: DaVita's ability to exceed EPS and revenue forecasts, alongside higher-than-expected revenue per treatment, indicates robust operational performance within its kidney care division.
- Divergent Analyst Sentiment: While some institutions have upgraded the stock with high price targets, others maintain cautious ratings despite upward target revisions, reflecting varied perspectives on the company's valuation.
Risks and Uncertainties
- Valuation Concerns: Analysis suggests the stock may be slightly overvalued relative to its Fair Value estimate, potentially placing it on lists of most overvalued companies. This poses a risk to the broader healthcare equity market if corrections occur.
- Market Volatility: Despite positive earnings, DaVita's stock has experienced declines in aftermarket trading due to wider market volatility, illustrating how macro-economic shifts can impact even strong performers.